Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project

BACKGROUND: On 30 January 2012, the US FDA approved vismodegib (Erivedge(®), Genentech, CA, USA) for the management of both metastatic and locally advanced basal cell carcinoma. OBJECTIVE: Our objective was to identify evidence of hepatotoxicity with vismodegib in the FDA Adverse Event Reporting Sys...

Descripción completa

Detalles Bibliográficos
Autores principales: Edwards, Beatrice J., Raisch, Dennis W., Saraykar, Smita S., Sun, Ming, Hammel, Josh A., Tran, Hai T., Wehr, Nathaniel, Arabyat, Rasha, West, Dennis P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318336/
https://www.ncbi.nlm.nih.gov/pubmed/28063021
http://dx.doi.org/10.1007/s40268-016-0168-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318336/
https://www.ncbi.nlm.nih.gov/pubmed/28063021
http://dx.doi.org/10.1007/s40268-016-0168-2

Ejemplares similares